Literature DB >> 8983072

Matrix-degrading metalloproteinases in tumor progression.

L M Matrisian1, J Wright, K Newell, J P Witty.   

Abstract

The matrix-degrading metalloproteinases (MMPs) have been implicated in tumor invasion and metastasis. Recently it has become clear that the expression of MMPs in tumors is frequently localized to stromal cells surrounding malignant tumor cells. In the mouse skin model of multi-stage carcinogenesis, the MMP stromelysin is expressed in stromal fibroblast-like cells surrounding benign and malignant squamous cell carcinomas. Conversion of these tumors to highly invasive and metastatic spindle-cell tumors is however, associated with the expression of stromelysin-1 mRNA in the tumor cells themselves. The analysis of MMPs in human colon adenocarcinomas at different stages of tumor progression revealed that matrilysin was the only MMP expressed in the tumor cells, while stromelysin-1 and stromelysin-3 mRNA was detected in stromal cells surrounding malignant tumor cells. Matrilysin mRNA is detected in benign tumors as well as malignant tumor cells, and the relative level and percent of tumors expressing matrilysin correlates with the stage of tumor progression. These results suggest that both stromal and tumor cell metalloproteinases may contribute to tumor invasion and metastasis, and also suggests that MMPs may play a role in earlier events in the tumor progression pathway. A potential role for MMPs in tumor growth is illustrated by results which suggest that the expression of matrilysin in human colon cancer-derived cells increases tumorigenicity following injection into the cecum, and that transgenic mice expressing matrilysin mRNA show a marked proliferative response. MMPs may therefore play multiple roles in tumor progression.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8983072

Source DB:  PubMed          Journal:  Princess Takamatsu Symp


  15 in total

1.  The forkhead box transcription factor FOXC1 promotes breast cancer invasion by inducing matrix metalloprotease 7 (MMP7) expression.

Authors:  Steven T Sizemore; Ruth A Keri
Journal:  J Biol Chem       Date:  2012-05-29       Impact factor: 5.157

2.  Chemical Tumor Biology of Heparan Sulfate Proteoglycans.

Authors:  Karthik Raman; Balagurunathan Kuberan
Journal:  Curr Chem Biol       Date:  2010-01-01

3.  Proteolysis in colorectal cancer.

Authors:  E A Garbett; M W Reed; N J Brown
Journal:  Mol Pathol       Date:  1999-06

Review 4.  Matrix metalloproteinases as novel biomarkers and potential therapeutic targets in human cancer.

Authors:  Roopali Roy; Jiang Yang; Marsha A Moses
Journal:  J Clin Oncol       Date:  2009-09-08       Impact factor: 44.544

5.  Metastatic conversion of chemically transformed human cells.

Authors:  X L Sun; D Li; J Fang; B Casto; I Noyes; G E Milo
Journal:  Gene Expr       Date:  1999

6.  Hypoxia-induced gene expression in human macrophages: implications for ischemic tissues and hypoxia-regulated gene therapy.

Authors:  Bernard Burke; Athina Giannoudis; Kevin P Corke; Dalvir Gill; Michael Wells; Loems Ziegler-Heitbrock; Claire E Lewis
Journal:  Am J Pathol       Date:  2003-10       Impact factor: 4.307

7.  Rodent pharmacokinetic and anti-tumor efficacy studies with a series of synthetic inhibitors of matrix metalloproteinases.

Authors:  O Santos; C D McDermott; R G Daniels; K Appelt
Journal:  Clin Exp Metastasis       Date:  1997-09       Impact factor: 5.150

Review 8.  Endocannabinoids and reactive nitrogen and oxygen species in neuropathologies.

Authors:  Allyn C Howlett; Somnath Mukhopadhyay; Derek C Norford
Journal:  J Neuroimmune Pharmacol       Date:  2006-06-24       Impact factor: 4.147

9.  Matrix metalloproteinase 7 controls pancreatic acinar cell transdifferentiation by activating the Notch signaling pathway.

Authors:  Eric T Sawey; Johnny A Johnson; Howard C Crawford
Journal:  Proc Natl Acad Sci U S A       Date:  2007-11-27       Impact factor: 11.205

10.  Sample prep for proteomics of breast cancer: proteomics and gene ontology reveal dramatic differences in protein solubilization preferences of radioimmunoprecipitation assay and urea lysis buffers.

Authors:  Lambert C M Ngoka
Journal:  Proteome Sci       Date:  2008-10-24       Impact factor: 2.480

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.